Compare Biogen Inc (BIIB) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Raytheon Technologies Corp — how do they compare? Biogen Inc trades at $195.34 (market cap $28.34B), while Raytheon Technologies Corp trades at $194.6 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 9.2× Biogen Inc's market cap, and Raytheon Technologies Corp pays a 1.51% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | RTX | |
|---|---|---|
Market Cap | $28.34B | $260.44B |
Sector | Health | Industrials |
52-Week High | $216.63 | $212.16 |
52-Week Low | $122.68 | $148.68 |
Enterprise Value | $30.62B | $292.55B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
RTX trades at $196.39, up 0.23% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $1.78 surpassing the $1.51 expectation. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. The company secured a $515 million Navy contract for SPY-6 radars, highlighting defense sector strength. Cash flow from operations reached $10.57B in 2025, supporting dividend payments and strategic investments.
The outlook for RTX is positive, driven by robust defense contracts, earnings growth, and a consensus price target of $213. Risks include reliance on government spending, competitive pressures, and macroeconomic volatility. Institutional sentiment remains bullish with 69% buy ratings, but investors should monitor debt levels and execution on production targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
